iTeos Therapeutics, Inc. (ITOS) — Financial statements
Income statement, balance sheet, and cash flow for iTeos Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 35↑177.9% | 13↓95.3% | 268↓22.4% | 345 | 0.00 | |
| Cost of Revenue | 1↑37.9% | 0.90↑10.5% | 0.81↑32.2% | 0.62↑15.0% | 0.54 | |
| Gross Profit | 34↑188.6% | 12↓95.6% | 267↓22.5% | 344↑64429.0% | -0.54 | |
| Operating Expenses | ||||||
| R&D Expenses | 145↑28.4% | 113↑16.4% | 97↑64.0% | 59↑98.6% | 30 | |
| General & Administrative Expenses | 49↓2.6% | 50↑14.7% | 44↑8.5% | 41↑164.0% | 15 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 49↓2.6% | 50↑14.7% | 44↑8.5% | 41↑164.0% | 15 | |
| Other Expenses | -1↓37.9% | -0.90↓10.5% | -0.81↓32.2% | -0.62↓15.0% | -0.54 | |
| Operating Expenses | 193↑18.7% | 163↑15.9% | 140↑41.5% | 99↑122.0% | 45 | |
| Total Costs & Expenses | 195↑18.8% | 164↑15.8% | 141↑41.5% | 100↑120.8% | 45 | |
| Operating Results | ||||||
| Operating Income | -160↓5.6% | -151↓219.6% | 126↓48.4% | 245↑641.3% | -45 | |
| Depreciation & Amortization | 1↑37.9% | 0.90↑10.5% | 0.81↑32.2% | 0.62↑15.0% | 0.54 | |
| EBITDA | -122↓9.1% | -112↓175.3% | 148↓42.3% | 257↑779.4% | -38 | |
| EBIT | -123↓9.3% | -113↓176.3% | 148↓42.5% | 256↑768.3% | -38 | |
| Interest & Other Income | ||||||
| Net Interest Income | 31↓2.8% | 32↑179.7% | 11↑14465.4% | 0.08 | 0.00 | |
| Interest Income | 31↓2.8% | 32↑179.7% | 11↑14465.4% | 0.08 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -36↑5.4% | -39↓81.5% | -21↓83.7% | -12↓68.5% | -7 | |
| Other Income / Expenses | 39↓6.9% | 42↑87.7% | 22↑93.8% | 12↑61.7% | 7 | |
| Income Before Tax | -120↓10.4% | -109↓173.3% | 149↓42.0% | 256↑773.3% | -38 | |
| Income Tax Expense | 14↑289.6% | 4↓93.1% | 52↑24.2% | 42↑73684.2% | -0.06 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -134↓19.3% | -113↓216.5% | 97↓54.9% | 215↑664.0% | -38 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -134↓19.3% | -113↓216.5% | 97↓54.9% | 215↑664.0% | -38 | |
| Bottom-Line Net Income | -134↓19.3% | -113↓216.5% | 97↓54.9% | 215↑594.3% | -43 | |
| EPS (Basic) | -3.32↓5.4% | -3.15↓215.8% | 2.72↓55.4% | 6.10↑591.9% | -1.24 | |
| EPS (Diluted) | -3.32↓5.4% | -3.15↓223.0% | 2.56↓54.9% | 5.68↑558.1% | -1.24 | |
| Weighted Average Shares | 40↑13.2% | 36↑0.6% | 36↑1.1% | 35↑0.4% | 35 | |
| Weighted Average Diluted Shares | 40↑13.2% | 36↓5.3% | 38↓0.0% | 38↑7.8% | 35 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.